In one paragraphObservational study in Clinical pharmacology and therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
9 authors.
Danwei ShaoDivision of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.ORCID 0009-0006-4737-4239 Jean G MalavéDepartment of Pharmacotherapy & Translational Research and Center for Pharmacogenomics and Precision Medicine, College of Pharmacy, University of Florida, Gainesville, Florida, USA.ORCID 0009-0004-6240-4876 Joseph S RossiDivision of Cardiology and McAllister Heart Institute, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Francesco FranchiDivision of Cardiology, Department of Medicine, College of Medicine-Jacksonville, University of Florida, Jacksonville, Florida, USA.ORCID 0000-0001-8503-5736 Ellen C KeeleyDivision of Cardiovascular Medicine, College of Medicine, University of Florida, Gainesville, Florida, USA.ORCID 0000-0003-2915-4751 Dominick J AngiolilloDivision of Cardiology, Department of Medicine, College of Medicine-Jacksonville, University of Florida, Jacksonville, Florida, USA.ORCID 0000-0001-8451-2131 George A StoufferDivision of Cardiology and McAllister Heart Institute, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Larisa H Cavallari *Department of Pharmacotherapy & Translational Research and Center for Pharmacogenomics and Precision Medicine, College of Pharmacy, University of Florida, Gainesville, Florida, USA.ORCID 0000-0002-7184-5292 Craig R Lee *Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.ORCID 0000-0003-3595-5301 Funding
North Carolina Translational and Clinical Sciences Institute (NC TraCS)UM1TR004406 · NCATS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI NICHOLAS J SHAHEEN · 2023 to 2026
$37.5MSparking Advancements in Genomic MedicineU01HG007269 · NHGRI · UNIVERSITY OF FLORIDA · PI CAVALLARI, LARISA HUMMA, JOHNSON, JULIE A. · 2013 to 2024
$17.0MINSiGHTS - Innovative Next Steps in Gaining Health Improvements Through Translational ScienceUM1TR005128 · NCATS · UNIVERSITY OF FLORIDA · PI DUANE A. MITCHELL, SYLVIE NAAR · 2025 to 2026
$10.7MUNC-Duke Collaborative Clinical Pharmacology Postdoctoral Training Program-Evaluation SupplementT32GM086330 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KIM L.R. BROUWER, Daniel Gonzalez · 2011 to 2026
$8.5MTraining Program for Applied Research and Development in Genomic MedicineT32HG008958 · NHGRI · UNIVERSITY OF FLORIDA · PI Larisa Humma Cavallari, Stephen E. Kimmel · 2018 to 2026
$3.8MPrecision antiplatelet therapy after percutaneous coronary interventionR01HL149752 · NHLBI · UNIVERSITY OF FLORIDA · PI CAVALLARI, LARISA HUMMA, LEE, CRAIG R · 2020 to 2024
$3.5MNational Institutes of Health (NIH) National Heart, Lung, and Blood Institute R01HL149752NCATS NIH HHS UM1 TR004406NCATS NIH HHS UM1TR004406NCATS NIH HHS UM1 TR005128NCATS NIH HHS UM1TR005128NHGRI NIH HHS T32 HG008958NHGRI NIH HHS T32HG008958NHGRI NIH HHS U01 HG007269NHGRI NIH HHS U01HG007269NHLBI NIH HHS R01 HL149752NIGMS NIH HHS T32 GM086330NIGMS NIH HHS T32GM086330
6 · The paper itselfAbstract
CYP2C19 and CYP3A4 contribute to clopidogrel bioactivation. CYP2C19 no-function alleles diminish clopidogrel's antiplatelet effects and clinical effectiveness. Coadministration of either a CYP2C19 or a CYP3A4 inhibitor may also reduce clopidogrel's antiplatelet effects and lead to phenoconversion in patients without a CYP2C19 no-function allele (normal/rapid/ultrarapid metabolizers: NM/RM/UMs). However, the impact of CYP2C19 or CYP3A4 inhibitor use on clopidogrel clinical effectiveness remains unclear. Rates of major atherothrombotic events (MAE) over 12 months after percutaneous coronary intervention (PCI) were evaluated in 3,242 patients across three sites who underwent CYP2C19 genotype testing and received P2Y
Indexed as
ClopidogrelCytochrome P-450 CYP2C19Cytochrome P-450 CYP2C19 InhibitorsCytochrome P-450 CYP3ACytochrome P-450 CYP3A InhibitorsPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsTiclopidineAgedDrug InteractionsFemaleGenotypeHumansMaleMiddle AgedTreatment OutcomeClopidogrelCYP2C19 protein, humanCYP3A4 protein, humanCytochrome P-450 CYP2C19Cytochrome P-450 CYP2C19 InhibitorsCytochrome P-450 CYP3ACytochrome P-450 CYP3A InhibitorsPlatelet Aggregation InhibitorsTiclopidine
Identifiers
PMID42138382
PMCPMC13339003
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390